Canntab Therapeutics Limited
CTABF
$0.00
$0.000.00%
OTC PK
| 02/28/2023 | 11/30/2022 | 08/31/2022 | 05/31/2022 | 02/28/2022 | |
|---|---|---|---|---|---|
| Net Income | 59.99% | -110.69% | 68.06% | -245.27% | 66.19% |
| Total Depreciation and Amortization | -46.78% | 18.18% | -27.36% | 72.96% | -10.06% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -58.32% | 1,358.13% | -107.79% | 281.77% | -148.65% |
| Change in Net Operating Assets | -77.99% | 257.80% | -239.28% | 72.04% | -33.89% |
| Cash from Operations | 34.35% | 89.60% | 33.31% | -2.56% | -17.31% |
| Capital Expenditure | -- | -- | -- | -100.00% | 125.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -100.00% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 77.17% | -- | -- | 36.97% | -2,162.50% |
| Cash from Investing | 77.17% | -- | -- | -106.04% | 43,150.00% |
| Total Debt Issued | -- | -- | -- | -100.00% | -- |
| Total Debt Repaid | 109.95% | -6.35% | -6.78% | -7.27% | -7.14% |
| Issuance of Common Stock | -- | -- | -- | -100.00% | 5,594.67% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 110.07% | -1.36% | -5.76% | -101.03% | 21,457.14% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 57.27% | 84.25% | 33.55% | -169.27% | 278.23% |